**November 2003:**
Diagnosis of *Clinical Isolated Syndrome* (CIS) following an episode of optic neuritis (EDSS 2.0).
MRI showed multiple T2/FLAIR lesions and no Gd+ lesions.
Spinal tap performed in January 2004 (no Oligoclonal Bands).
Normal multimodal evoked potentials (Visual, Motor and Somatosensory) with the exception of left eye visual evoked potential.

**February 2005:**
Diagnosis of *Clinically defined Multiple Sclerosis* (CDMS) after the first relapse of optic neuritis (EDSS 2.0).
MRI showed multiple new T2/FLAIR lesions with Gd+ enhancing lesions.

**Immunomodulation is started**

**First-line therapy:**
- February 2005: Avonex
- December 2005: Rebif 44
- February 2007: Copaxone

All first-line agents were suspended due to lack of efficacy and increased MRI lesion load.
EDSS 3.0

**Second-line therapy:**
- March 2008: Tysabri (negative Stratify JCV test)
- June 2011: positive Stratify JCV, Tysabri is withdrawn (about 40 infusions)
- October 2011: Gilenya (after a 3 months wash-out)

Second-line agents were extremely effective reducing relapses and MRI activity.
EDSS 3.0

**March 2013: Upon patient desire and after a neurological consult Gilenya is discontinued in order to begin a pregnancy**

**Pregnancy starts in April 2013**

**July 2013 (11th week of pregnancy)**
Severe relapse with cognitive impairment, tetraparesis and dysphagia, EDSS 9.0
Patient is treated with i.v. steroid with partial remission, EDSS 7.0

**An abortion was carried out and the patient was treated with Cyclophosphamide 2g/m²**

**A spinal tap was also performed in order to exclude Herpes and JCV infections**

Despite the effect of the immunosuppressive therapy, the patient further relapsed and then suffered a septic shock by Gram negative, multi-drug resistant bacteria that led to patient death on February 2014.

**MRI after the relapse of August 2013**

**Two hypothesis were made:**

**Disease rebound due to Fingolimod withdrawal?**
- Few reports of Multiple Sclerosis rebound after Fingolimod suspension, just one case during pregnancy.

**PML/PML-IRIS?**
- To date no cases of PML during or after Fingolimod suspension have been reported.

---

1. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Italy
2. S. Paolo Hospital, Savona, Italy

**References:**